anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sumavel DosePro is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of Sumavel DosePro. Some of these reactions occurred in patients without known CAD. Sumavel DosePro may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD. 

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving Sumavel DosePro. If there is evidence of CAD or coronary artery vasospasm, Sumavel DosePro is contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of Sumavel DosePro in a medically supervised setting and performing an electrocardiogram (ECG) immediately following Sumavel DosePro. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of Sumavel DosePro.
The present invention provides for a real-time communication channel between a portable healthcare device and a remote information site. The health information system allows for transfer operations to be performed on-line and at any time. The health-related information is transmitted by one end of a network pathway and travels to a second end of the pathway. Along the pathway, the information is progressively intercepted by each of a series of segments having an interface to prepare the health-related information with appropriate data for reading at the next segment along the network pathway. The information is immediately processed and relayed back into the network towards its destination. In one embodiment, back-end services are provided for front-end applications occurring at a portable healthcare device, such as processing of raw health-related information generated at the portable healthcare device. In addition, other aspects of the present invention relating to the communication of health-related information between disparate segments to transfer the information.
Drugs Dependent on Gastric pH for Absorption

Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. See the prescribing information for other drugs dependent on gastric pH for absorption.

Tizanidine (CYP1A2 Substrate)

Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor. Concomitant use of tizanidine, a CYP1A2 substrate, with famotidine may lead to increased exposure of tizanidine and adverse reactions of hypotension, bradycardia or excessive drowsiness. Avoid concomitant use with famotidine. If use is clinically necessary, refer to the full prescribing information for tizanidine for dosage information.
PROBLEM TO BE SOLVED: To obtain a medicine composition for preventing or treating male sterility, capable of effectively preventing or treating male sterility, by including a sesame meal extract and/or an oyster extract. SOLUTION: This composition contains (A) a sesame meal extract and/or (B) an oyster extract. A sesame meal is mixed with water, heated to >=75 deg.C stirred for >=30 minutes and cooled to 20-70 deg.C to give (i) a sesame meal extract, which is adjusted to proper pH, reacted with a peptidase resistant to an acidic range, heated at >=75 deg.C for >=30 minutes, subjected to a filter press and centrifuged to give (ii) a crude sesame meal essence solution. Then the solution is concentrated, sterilized and dried to give (iii) sesame extract powder. The components (i), (ii) and (iii) are the component A. Crassostreagigas is treated with an enzyme to give (iv) a water-soluble essence, which is concentrated to give (v) a concentrated essence, which is dried to give (vi) oyster essence powder. The components (iv), (v) and (vi) are the component B.
Systems and methods for automatic health data processing are disclosed. One or more complaints are extracted from question and answer data of an automated patient interview. A parent-child symptom mapping is referenced to identify a respective parent symptom corresponding to each complaint. Based on the question and answer data, a presence or absence of evidence of the child symptoms associated with each identified parent symptom is determined. The child symptoms are categorized into a positive or negative category based on the determination. An object is generated that includes, for each of the complaints, a positive and negative list of any of the child symptoms included in the positive and negative category, respectively. The object is processed to generate a history of present illness (HPI) portion of a notation in a graphical format. The notation is stored in the patient's electronic health record, and a healthcare provider notification is transmitted.
Despite the substantial number of work published over the past years in different populations around the world, a fundamental gap remains in understanding whether and how genomic admixture and polymorphisms in warfarin-related pharmacogenes account for the high inter-individual dose variability observed in Caribbean Hispanic patients. In addition to being a medically underserved population, often marginally represented in clinical studies, Caribbean Hispanics are also a genomically heterogeneous population whose high level of admixture has produced a rich repertoire of combinatorial genotypes (e.g., CYP2C9\*2/\*5 + VKORC1-1639 A/A) that appear to challenge current pharmacogenetic-driven prescribing models. Our project takes a novel approach to definitively assess this admixture component and is also highly practical for its incorporation into a customized pharmacogenetic algorithm that will be implemented in "real-world" clinical settings through a web-based portal. Moreover, the project is also aimed at performing DNA-sequencing to identify those unknown variants on candidate pharmacogenes (i.e., CYP2C9 and VKORC1) that may contribute further to explain dose variability in Caribbean Hispanics. Shaped by strong preliminary data from a SC2 pilot project, the investigators will assess clinical validity and utility of an admixture-adjusted, pharmacogenetic-guided prescribing model for personalized prediction of effective warfarin dosing in Caribbean Hispanics, which also encompasses genetic (common and novel variants) and non-genetic clinical and demographic factors. The study will be conducted over 4 years in 300 patients with thromboembolic disorders receiving warfarin. Four collaborating/recruiting sites will be further connected through precise delivery of genotyping results and prescribing advice to clinicians via a web-based portal. Our novel assessment of genetic admixture will quantify the contribution of European, African and Amerindian ancestry, and the investigators will test whether this admixture component can explain the heritability that is currently missing in the response variability to this drug among Caribbean Hispanics. If successful in our target population, the same approach can ultimately render current pharmacogenomic models for clinical management of related thromboembolic conditions more accurate and predictive for other populations.

The proposed research will advance and expand our understanding of how these clinically relevant variants affect the response to warfarin in an admixed population. Advancing knowledge in the important and under-investigated area of pharmacogenetics in minority populations will generate results that apply to personalize oral anticoagulation therapy in the wider population as it moves, inevitably, toward increasing heterogeneity through admixed genomes.
Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
PURPOSE:To provide the subject highly safe composition having the remarkably heightened absorbability of drugs from membrane mucosas and having excellent compatibility with living bodies by compounding a drug and hyaluronic acid (salt). CONSTITUTION:The objective composition contains a drug, e.g. a peptide hormone such as vasopressin, calcitonin or insulin or a derivative thereof such as desmopressin and hyaluronic acid or a salt (preferably Na salt) thereof. The hyaluronic acid (salt) is compounded in an amount of 0.0001-2wt.%, preferably 0.1-1.5wt.%, based on the unhole amount of the composition. The pH of the drug composition is preferably 4-8 from the points of the phyriological environment of human mucosa and the stability of the hyaluronic acid, especially providing an excellent drug absorption-accelerating effect at a pH near 4. The addition of a protease inhibitor to the composition on the employment of the peptide drug further increases the effect.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including ramipril, may be associated with oliguria or progressive azotemia and rarely with acute renal failure or death.  
  
In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. In such patients, monitor renal function during the first few weeks of therapy. Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when ramipril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction of ramipril and/or discontinuation of the diuretic may be required.
<P>PROBLEM TO BE SOLVED: To provide a means for improving newly required qualities such as the colorless transparency of coating films themselves and the dispersion stability of the pearl gloss agent in a nail cosmetic which contains a pearl gloss agent.  <P>SOLUTION: This nail cosmetic comprising nitrocellulose and an alkyd resin is characterized by containing the pearl gloss agent and octocrylene. The content of the nitrocellulose is preferably 1 to 20 mass%, and the alkyd resin is preferably 1 to 15 mass%. The content of the octocrylene is preferably 0.1 to 5 mass%. It is preferable to contain small laminated resin pieces as the pearl gloss agent.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Valvular heart disease leads to ventricular pressure and/or volume overload. Pressure overload leads to fibrosis, which might regress with its resolution, but the limits and details of this reverse remodeling are not known. To gain more insight into the extent and nature of cardiac fibrosis in valve disease, we analyzed needle biopsies taken from the interventricular septum of patients undergoing surgery for valve replacement focusing on the expression and distribution of major extracellular matrix protein involved in this process. Proteomic analysis performed using mass spectrometry revealed an excellent correlation between the expression of collagen type I and III, but there was little correlation with the immunohistochemical staining performed on sister sections, which included antibodies against collagen I, III, fibronectin, sarcomeric actin, and histochemistry for wheat germ agglutinin. Surprisingly, the immunofluorescence intensity did not correlate significantly with the gold standard for fibrosis quantification, which was performed using Picrosirius Red (PSR) staining, unless multiplexed on the same tissue section. There was also little correlation between the immunohistochemical markers and pressure gradient severity. It appears that at least in humans, the immunohistochemical pattern of fibrosis is not clearly correlated with standard Picrosirius Red staining on sister sections or quantitative proteomic data, possibly due to tissue heterogeneity at microscale, comorbidities, or other patient-specific factors. For precise correlation of different types of staining, multiplexing on the same section is the best approach.
BACKGROUND & AIMS: Steatotic liver disease (SLD), characterized by elevated liver fat content (LFC), is influenced by genetics and diet. However, whether diet has a differential effect based on genetic risk is not well-characterized. We aimed to determine how genetic factors interact with diet to affect SLD in a large national biobank.
METHODS: We included UK Biobank participants with dietary intake measured by 24-hour recall and genotyping. The primary predictors were dietary pattern, PNPLA3-rs738409-G, TM6SF2-rs58542926-T, a 16-variant hepatic steatosis polygenic risk score (PRS), and gene-environment interactions. The primary outcome was LFC, and secondary outcomes were iron-controlled T1 time (cT1, a measure of liver inflammation and fibrosis) and liver-related events/mortality.
RESULTS: A total of 21,619 participants met inclusion criteria. In non-interaction models, Mediterranean diet and intake of fruit/vegetables/legumes and fish associated with lower LFC, while higher red/processed meat intake and all genetic predictors associated with higher LFC. In interaction models, all genetic predictors interacted with Mediterranean diet and fruit/vegetable/legume intake, while the steatosis PRS interacted with fish intake and the TM6SF2 genotype interacted with red/processed meat intake, to affect LFC. Dietary effects on LFC were up to 3.8-fold higher in PNPLA3-rs738409-GG vs. -CC individuals, and 1.4-3.0-fold higher in the top vs. bottom quartile of the steatosis PRS. Gene-diet interactions were stronger in participants with vs. without overweight. The steatosis PRS interacted with Mediterranean diet and fruit/vegetable/legume intake to affect cT1 and most dietary and genetic predictors associated with risk of liver-related events or mortality by age 70.
CONCLUSIONS: Effects of diet on LFC and cT1 were markedly accentuated in patients at increased genetic risk for SLD, implying dietary interventions may be more impactful in these populations.
IMPACT AND IMPLICATIONS: Genetic variants and diet both influence risk of hepatic steatosis, inflammation/fibrosis, and hepatic decompensation; however, how gene-diet interactions influence these outcomes has previously not been comprehensively characterized. We investigated this topic in the community-based UK Biobank and found that genetic risk and dietary quality interacted to influence hepatic steatosis and inflammation/fibrosis on liver MRI, so that the effects of diet were greater in people at elevated genetic risk. These results are relevant for patients and medical providers because they show that genetic risk is not fixed (i.e. modifiable factors can mitigate or exacerbate this risk) and realistic dietary changes may result in meaningful improvement in liver steatosis and inflammation/fibrosis. As genotyping becomes more routinely used in clinical practice, patients identified to be at high baseline genetic risk may benefit even more from intensive dietary counseling than those at lower risk, though future prospective studies are required.
This study aimed to critically evaluate the information provided by ChatGPT on the role of lactate in fatigue and muscle pain during physical exercise. We inserted the prompt "What is the cause of fatigue and pain during exercise?" using ChatGPT versions 3.5 and 4o. In both versions, ChatGPT associated muscle fatigue with glycogen depletion and "lactic acid" accumulation, whereas pain was linked to processes such as inflammation and microtrauma. We deepened the investigation with ChatGPT 3.5, implementing user feedback to question the accuracy of the information about lactate. The response was then reformulated, involving a scientific debate about the true role of lactate in physical exercise and debunking the idea that it is the primary cause of muscle fatigue and pain. We also utilized the creation of a "well-crafted prompt," which included persona identification and thematic characterization, resulting in much more accurate information in both the ChatGPT 3.5 and 4o models, presenting a range of information from the physiological process of lactate to its true role in physical exercise. The results indicated that the accuracy of the responses provided by ChatGPT can vary depending on the data available in its database and, more importantly, on how the question is formulated. Therefore, it is indispensable that educators guide their students in the processes of managing the AI tool to mitigate risks of misinformation.NEW & NOTEWORTHY Generative artificial intelligence (AI), exemplified by ChatGPT, provides immediate and easily accessible answers about lactate and exercise. However, the reliability of this information may fluctuate, contingent upon the scope and intricacy of the knowledge derived from the training process before most recent update. Furthermore, a deep understanding of the basic principles of human physiology becomes crucial for the effective correction and safe use of this technology.
By gestational age and birth weight, infants were classified into 3 groups. No interventions because of an observational study.
This Phase 1-2a study is an open label, dose-ranging study of TLK199 Tablets in patients with all World Health Organization or French-American-British classification types of myelodysplastic syndrome (MDS). In Phase 1, the safety, pharmacokinetics, and hematologic response rate with TLK199 Tablets will be evaluated. The Phase 1 dose-ranging stage is designed to determine the maximum tolerated dose or optimal biologic dose of TLK199 Tablets. Evaluation of the pharmacokinetics of TLK199 Tablets will be conducted. In Phase 1, an additional 12 patients will undergo pharmacokinetic evaluation under fed conditions at the selected Phase 2a dose. In Phase 2a, further safety and hematologic responses by the modified International Working Group MDS response criteria will be studied.
Major depressive disorder (MDD), or clinical depression, is a psychiatric disorder characterized by 2 or more weeks of persistently depressed mood accompanied by symptoms such as feelings of worthlessness, guilt, hopelessness, helplessness, loss of self-esteem, sleep disturbance, changes in oral intake, anhedonia, loss of interest, and suicidality. The american psychiatric association, on the definition of anxiety, describes anxiety as the anticipated anticipation of a future danger or negative event, accompanied by feelings of dysphoria or physical symptoms of tension. The elements exposed to risk may belong both to the internal world and to the external world. depression is highly prevalent globally and is a leading cause of disability. The global burden of disease study found depression to be a leading cause of disability among all illnesses. Liver cirrhosis is one of the diseases commonly associated with depression.chronic liver disease is the progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis (normally lasts 6 months). The etiologic agents of CLD include hepatotropic viruses (HBV and HCV), fatty liver, alcohol, autoimmune hepatitis, etc. The mortality of CLD patients remains high not only due to irreversible cirrhosis, but also multiple complications such as HCC and mental disease, especially depression. The progressive nature of this disease results in high rates of hospitalization, extensive exposure to medications, increased financial burden, frequent need for invasive procedures, changes in body image, and an increase in morbidity and mortality. All these factors contribute to the physical and psychological stress that mediates the development of depressive symptom high rates of depression have been documented in patients with decompensated liver disease and in those anticipating liver transplantation.
BACKGROUND: Posterior reversible encephalopathy syndrome is a rare neurological syndrome that refers to reversible subcortical vasogenic brain edema disorder in patients with acute neurological symptoms.
CASE PRESENTATION: Whether there is a direct causal relationship between pancreatitis and posterior reversible encephalopathy syndrome needs further study. We here report a 39-year-old Chinese woman who was diagnosed with pancreatitis followed by vision disturbance. The patient was finally diagnosed with posterior reversible encephalopathy syndrome. On the basis of this rare case, we analyzed the causes of visual disturbance and proposed diagnostic ideas.
CONCLUSIONS: For posterior reversible encephalopathy syndrome, early identification and treatment of the primary disease are particularly important. Imaging and clinical characteristics in posterior reversible encephalopathy syndrome are usually reversible.
Spirometry is a standard pulmonary function test that measures how an individual inhales or exhales volumes of air as a function time. It is the most important and most frequently performed pulmonary function testing procedure, having become indispensable for the prevention, diagnosis and evaluation of various respiratory impairments. However, there have been only a few studies addressing the effect of physical activity on pulmonary function test results and investigating the association between body composition and respiratory parameters in sports activities \[1,2,3\]. The objective of this study was verify if there are differences in spirometry values in children aged between 6 and 12 years who practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®. For the analysis of the results, we used descriptive statistics, the Shapiro Wilk test for testing the normality of the sample and for the inferential statistics the Mann-Whitney tests, Friedman's Anova, and d-Cohen for the magnitude of effect.
The invention relates to an atorvastatin calcium composition. Specifically, the invention relates to a novel and stable solid drug formula which is particularly suitable for treating hypercholesterolemia or coronary heart disease. Particularly, the invention relates to a novel and stable solid drug formula which contains an active material HMG-CoA reductase inhibitor, namely atorvastatin or a pharmaceutically active salt thereof. The solid pharmaceutical composition disclosed by the invention contains atorvastatin calcium, lipid substances, saccharides and optional pharmaceutical excipients. The solid pharmaceutical composition disclosed by the invention has excellent properties, e.g. chemical properties.